Video

Krista Qualmann on the Effect of Genetic Testing on Treatment in Brain Cancer

Krista Qualmann, MS, CGC, genetic counselor at the Memorial Hermann Mischer Neuroscience Institute at the Texas Medical Center and UTHealth, discusses the implications that genetic testing results can have on treatment options for patients with brain cancer.

For some hereditary syndromes, certain treatments might be more or less effective. As an example, patients with low-grade gliomas and certain syndromes should avoid ionizing radiation, Qualmann says. Additionally, testing is important to keep in mind when considering screening for other cancers. Many syndromes, including Li-Fraumeni syndrome, can put a patient at higher risk for other cancer types.

<<<

View more from the 2016 SNO Annual Meeting

Related Videos
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
Massimo Cristofanilli, MD, attending physician, NewYork-Presbyterian Hospital; professor, medicine, Weill Cornell Medical College, Cornell University
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for NVL-655 in ALK-positive NSCLC and other ALK-positive solid tumors.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss testing for ALK-positive and ROS1-positive non–small cell lung cancer.
Marc Machaalani, MD
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO